AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00736944
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
Trial: NCT00736944
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Trial: NCT00736944
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
Trial: NCT00736944
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
Trial: NCT03150602
Drug: Pralatrexate
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
Trial: NCT01706471
Drug: Everolimus + Low dose CsA +PD
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
Trial: NCT01706471
Drug: Myfortic+ Standard CsA + PD
RxNorm normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
Trial: NCT02636907
Drug: BI 695501 Autoinjector
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02636907
Drug: BI 695501 Prefilled syringe
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003666
Drug: 6-hydroxymethylacylfulvene
RxNorm normalized name: 6-hydroxymethylacylfulvene
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
Trial: NCT00072124
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00072124
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00866593
Drug: Generic Escitalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/d or 20mg/d
Trial: NCT00866593
Drug: Innovator Escitalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/d or 20mg/d
Trial: NCT01921387
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01921387
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01921387
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01921387
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00385710
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depakine
Trial: NCT01998776
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 200ug four times daily
Trial: NCT04224480
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg of intravenous infusion every 3 weeks
Trial: NCT01036893
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: prucalopride 2 mg oral dosing o.d. for 6 days
Trial: NCT00043381
Drug: decitabine (5-aza-2'deoxycytidine)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01669226
Drug: PEip (weekly) and TCiv
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Trial: NCT01135641
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
Trial: NCT01135641
Drug: Ciclosporine
RxNorm normalized name: Ciclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02145676
Drug: placebo (normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
Trial: NCT03681431
Drug: Ceftriaxone 4g/ 24h
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
Trial: NCT04540068
Drug: Transforaminal Epidural Injection
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
Trial: NCT03830164
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03830164
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02272764
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally in a crossover design
Trial: NCT03681431
Drug: Ceftriaxone 2g/ 12h
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
Trial: NCT02272764
Drug: ALKS 5461
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered sublingually in a crossover design
Trial: NCT00527800
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
Trial: NCT00527800
Drug: Trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily dosing according to weight based guidelines
Trial: NCT01453075
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1.5 mg po bid
Trial: NCT02348385
Drug: Amphetamine
RxNorm normalized name: Amphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
Trial: NCT01684969
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg iv x one dose
Trial: NCT00460304
Drug: pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02661932
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis.
Trial: NCT03542422
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
Trial: NCT00023309
Drug: Lamivudine and adefovir
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (100 mg/day) and adefovir (10 mg/day)
Trial: NCT00023309
Drug: Adefovir alone
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (10 mg/day)
Trial: NCT02840409
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02840409
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00319033
Drug: bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01432977
Drug: paracetamol /droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01432977
Drug: paracetamol / ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01045096
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
Trial: NCT01045096
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
Trial: NCT01045096
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
Trial: NCT00674999
Drug: Polysporin/Bacitracin/Mycostatin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
Trial: NCT02246478
Drug: TAS-205
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals
Trial: NCT00850577
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 200 mg/m2, Q21days, 6 cycles
Trial: NCT00850577
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution, IV, AUC=6, Q21days, 6 cycles
Trial: NCT03536767
Drug: AG10
RxNorm normalized name: JAG101
DrugBank: JAG101 (DB18321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG10 800mg twice daily, oral administration
Trial: NCT02309827
Drug: PF-06651600 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
Trial: NCT01652001
Drug: Malic Acid
RxNorm normalized name: Malic Acid
DrugBank: Malic acid (DB12751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral spray for application into the oral cavity
Trial: NCT01096420
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses.
Trial: NCT03156062
Drug: Topical corticosteroids with salicylic acid
RxNorm normalized name: salicylic acid Topical Solution
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
Trial: NCT03397862
Drug: Donepezil TDS
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil patch
Trial: NCT03397862
Drug: Vehicle TDS
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT04320173
Drug: Lidocaine patch 1.8%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three patches are applied to the subject's back for 12 hours.
Trial: NCT04320173
Drug: Lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three patches are applied to the subject's back for 12 hours.
Trial: NCT04320173
Drug: Lidocaine medicated plaster 5%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three plasters are applied to the subject's back for 12 hours.
Trial: NCT02252731
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02252731
Drug: FG-4592
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03840057
Drug: Metoclopramide Injectable Solution
RxNorm normalized name: metoclopramide Injectable Solution
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
Trial: NCT03840057
Drug: Sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline is used as a placebo control.
Trial: NCT02731157
Drug: Rejuvesol
RxNorm normalized name: Adenine/Inosine/Sodium Phosphate, Dibasic/Sodium Phosphate, Monobasic/Sodium Pyruvate 34 MG/50 ML-1.34 GM/50 ML-500 MG/50 ML-200 MG/50 ML-550 MG/50 ML Injection Injectable [REJUVESOL]
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03920657
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dose of 3.5 mg/kg/day of DFX FCT
Trial: NCT02224144
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 1000 IU per day for 12 months
Trial: NCT02224144
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
Trial: NCT00339768
Drug: Amoxicillin/omeprazole
RxNorm normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
Trial: NCT04946383
Drug: Dasatinib plus Quercetin
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib plus Quercetin
Trial: NCT04433910
Drug: Convalesscent Plasma
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion
Trial: NCT00850577
Drug: CT-322
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, IV, 2 mg/kg, Q7days, Until PD
Trial: NCT00850577
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 15 mg/kg, Q21days, Until PD
Trial: NCT00850577
Drug: Bevacizumab placebo (ie saline solution)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
Trial: NCT03478930
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
Trial: NCT00463112
Drug: Sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02940912
Drug: Apomorphine
RxNorm normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
Trial: NCT00469274
Drug: Antibiotic PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
Trial: NCT00469274
Drug: Antibiotic PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMP-SMX DS po BID for 14 days
Trial: NCT03505008
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of Administration: Subcutaneous
Trial: NCT00105144
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00105144
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00242346
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00194948
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01065259
Drug: OROS MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
Trial: NCT01065259
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
Trial: NCT03889106
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.